We are live on ! Find out more
TGI

TRV GP II Portfolio holdings

AUM $1.34M
1-Year Est. Return 67.55%
This Fund
S&P 500
This Quarter Est. Return
+60.65%
1 Year Est. Return
-67.55%
3 Year Est. Return
-20.84%
5 Year Est. Return
-49.87%
10 Year Est. Return
AUM
$153M
AUM Growth
+$52.7M
Cap. Flow
-$3.58M
Cap. Flow %
-2.33%
Top 10 Hldgs %
100%
Holding
4
New
Increased
Reduced
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$3.58M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BPMC
1
DELISTED
Blueprint Medicines
BPMC
$70.4M 45.87%
878,875
JNCE
2
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$63.4M 41.35%
10,230,349
ALNA
3
DELISTED
Allena Pharmaceuticals
ALNA
$19.6M 12.77%
2,790,964
SAGE
4
DELISTED
Sage Therapeutics
SAGE
-37,362
Closed -$3.58M

Similar funds

TRV GP II's Q1 2019 Portfolio in Review

As of Q1 2019, TRV GP II held 4 positions worth $153M, up 52% from $101M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

TRV GP II's Q1 2019 filing shows 1 closed position. The largest sale was Sage Therapeutics, an estimated $3.58M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TRV GP II fully exited Sage Therapeutics in Q1 2019, selling an estimated $3.58M.
  • TRV GP II's ten largest holdings make up 100% of its $153M portfolio in Q1 2019.
  • TRV GP II opened 0 new positions and closed 1 in Q1 2019.
  • TRV GP II's portfolio value rose 52% quarter-over-quarter to $153M.

Based on TRV GP II's 13F filing for Q1 2019, filed 3 May 2019.